These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 20590706)

  • 21. Evaluation of the efficacy of polidocanol in the form of foam compared with liquid form in sclerotherapy of the greater saphenous vein: initial results.
    Hamel-Desnos C; Desnos P; Wollmann JC; Ouvry P; Mako S; Allaert FA
    Dermatol Surg; 2003 Dec; 29(12):1170-5; discussion 1175. PubMed ID: 14725657
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparative study of duplex-guided foam sclerotherapy and duplex-guided liquid sclerotherapy for the treatment of superficial venous insufficiency.
    Yamaki T; Nozaki M; Iwasaka S
    Dermatol Surg; 2004 May; 30(5):718-22; discussion 722. PubMed ID: 15099313
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ultrasound-guided foam sclerotherapy for the treatment of varicose veins.
    Darke SG; Baker SJ
    Br J Surg; 2006 Aug; 93(8):969-74. PubMed ID: 16739097
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Review of published information on foam sclerotherapy.
    Stücker M; Kobus S; Altmeyer P; Reich-Schupke S
    Dermatol Surg; 2010 Jun; 36 Suppl 2():983-92. PubMed ID: 20590705
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Embolia cutis medicamentosa of the foot after sclerotherapy.
    Geukens J; Rabe E; Bieber T
    Eur J Dermatol; 1999 Mar; 9(2):132-3. PubMed ID: 10066964
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Treatment of bleeding esophageal varices with cyanoacrylate and polidocanol, or polidocanol alone: results of a prospective study in an unselected group of patients with cirrhosis of the liver.
    Lux G; Retterspitz M; Stabenow-Lohbauer U; Langer M; Altendorf-Hofmann A; Bozkurt T
    Endoscopy; 1997 May; 29(4):241-6. PubMed ID: 9255525
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Significant endothelin release in patients treated with foam sclerotherapy.
    Frullini A; Barsotti MC; Santoni T; Duranti E; Burchielli S; Di Stefano R
    Dermatol Surg; 2012 May; 38(5):741-7. PubMed ID: 22540861
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Incidence of side effects in the treatment of telangiectasias by compression sclerotherapy: hypertonic saline vs. polidocanol.
    Weiss RA; Weiss MA
    J Dermatol Surg Oncol; 1990 Sep; 16(9):800-4. PubMed ID: 2398199
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Reversible ischaemic neurological deficit after sclerotherapy of varicose veins.
    Van der Plas JP; Lambers JC; Van Wersch JW; Koehler PJ
    Lancet; 1994 Feb; 343(8894):428. PubMed ID: 7905592
    [No Abstract]   [Full Text] [Related]  

  • 30. Localized retiform purpura after accidental intra-arterial injection of polidocanol.
    Yébenes M; Gilaberte M; Toll A; Barranco C; Pujol RM
    Acta Derm Venereol; 2005; 85(4):372-3. PubMed ID: 16191871
    [No Abstract]   [Full Text] [Related]  

  • 31. Ischaemic neurological deficit after sclerotherapy.
    Trenkwalder P; Lydtin H
    Lancet; 1994 Mar; 343(8900):794. PubMed ID: 7907752
    [No Abstract]   [Full Text] [Related]  

  • 32. Polidocanol (Varithena) for varicose veins.
    Med Lett Drugs Ther; 2015 Aug; 57(1474):111-2. PubMed ID: 26218793
    [No Abstract]   [Full Text] [Related]  

  • 33. Double-blind prospective comparative trial between foamed and liquid polidocanol and sodium tetradecyl sulfate in the treatment of varicose and telangiectatic leg veins.
    Rao J; Wildemore JK; Goldman MP
    Dermatol Surg; 2005 Jun; 31(6):631-5; discussion 635. PubMed ID: 15996411
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Polidocanol-foam treatment of varicose veins: Quality-of-life impact compared to conventional surgery.
    Sakugawa LS; Portela FSO; Louzada ACS; Portugal MFC; Teivelis MP; Mendes CA; Pinheiro LL; Silva MFAD; Fioranelli A; Wolosker N
    Clinics (Sao Paulo); 2024; 79():100346. PubMed ID: 38574572
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Polidocanol for endovenous microfoam sclerosant therapy.
    Eckmann DM
    Expert Opin Investig Drugs; 2009 Dec; 18(12):1919-27. PubMed ID: 19912070
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Sclerotherapy of telangiectases and reticular veins: a double-blind, randomized, comparative clinical trial of polidocanol, sodium tetradecyl sulphate and isotonic saline (EASI study).
    Rabe E; Schliephake D; Otto J; Breu FX; Pannier F
    Phlebology; 2010 Jun; 25(3):124-31. PubMed ID: 20483861
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Foam sclerotherapy: investigating the need for sterile air.
    de Roos KP; Groen L; Leenders AC
    Dermatol Surg; 2011 Aug; 37(8):1119-24. PubMed ID: 21615606
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Indications for the sclerosing agent polidocanol (aetoxisclerol dexo, aethoxisklerol kreussler).
    Guex JJ
    J Dermatol Surg Oncol; 1993 Oct; 19(10):959-61. PubMed ID: 8408916
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Reversible neurological deficit after foam sclerotherapy.
    Hartmann K; Harms L; Simon M
    Eur J Vasc Endovasc Surg; 2009 Nov; 38(5):648-9. PubMed ID: 19683463
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immediate and midterm complications of sclerotherapy: report of a prospective multicenter registry of 12,173 sclerotherapy sessions.
    Guex JJ; Allaert FA; Gillet JL; Chleir F
    Dermatol Surg; 2005 Feb; 31(2):123-8; discussion 128. PubMed ID: 15762201
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.